Global, regional and national incidence, mortality and disability-adjusted life-years of skin cancers and trend analysis from 1990 to 2019: An analysis of the Global Burden of Disease Study 2019
- PMID: 34105887
- PMCID: PMC8290243
- DOI: 10.1002/cam4.4046
Global, regional and national incidence, mortality and disability-adjusted life-years of skin cancers and trend analysis from 1990 to 2019: An analysis of the Global Burden of Disease Study 2019
Abstract
Background: Information about global and local epidemiology and trends of skin cancers is limited, which increases the difficulty of cutaneous cancer control.
Methods: To estimate the global spatial patterns and temporal trends of skin cancer burden. Based on the GBD 2019, we collected and analyzed numbers and age-standardized rates (ASR) of skin cancer incidence, disability-adjusted life years (DALYs) and mortality (ASIR, ASDR, and ASMR) in 204 countries from 1990 through 2019 were estimated by age, sex, subtype (malignant skin melanoma [MSM], squamous-cell carcinoma [SCC], and basal-cell carcinoma [BCC]), Socio-demographic Index (SDI), region, and country. Temporal trends in ASR were also analyzed using estimated annual percentage change.
Results: Globally, in 2019, there were 4.0 million BCC, 2.4 million SCC, and 0.3 million MSM. There were approximately 62.8 thousand deaths and 1.7 million DALYs due to MSM, and 56.1 thousand deaths and 1.2 million DALYs were attributed to SCC, respectively. The men had higher ASR of skin cancer burden than women. The age-specific rates of global skin cancer burden were higher in the older adults, increasing trends observed from 55 years old. Geographically, the numbers and ASR of skin cancers varied greatly across countries, with the largest burden of ASIR in high SDI regions. However, an unexpected increase was observed in some regions from 1990 to 2019, such as East Asia, and Sub-Saharan Africa. Although there was a slight decrease of the ASMR and ASDR, the global ASIR of MSM dramatically increased, 1990-2019. Also, there was a remarkable increase in ASR of BCC and SCC burden.
Conclusions: Skin cancer remains a major global public health threat. Reducing morbidity and mortality strategies such as primary and secondary prevention should be reconsidered, especially in the most prevalent and unexpected increased regions, especially for those areas with the greatest proportions of their population over age 55.
Keywords: basal-cell carcinoma; disability-adjusted life-years; global burden of disease; incidence; malignant skin melanoma; mortality; skin cancers; squamous-cell carcinoma.
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare to no conflicts of interest that pertain to this work.
Figures




Similar articles
-
Global burden of non-melanoma skin cancers among older adults: a comprehensive analysis using machine learning approaches.Sci Rep. 2025 May 1;15(1):15266. doi: 10.1038/s41598-025-99605-5. Sci Rep. 2025. PMID: 40312476 Free PMC article.
-
Global, regional, and national trends in the burden of melanoma and non-melanoma skin cancer: insights from the global burden of disease study 1990-2021.Sci Rep. 2025 Feb 18;15(1):5996. doi: 10.1038/s41598-025-90485-3. Sci Rep. 2025. PMID: 39966563 Free PMC article.
-
Analysis and comparison of the trends in burden of malignant cutaneous melanoma in East Asian countries and regions and worldwide from 1991 to 2021.Front Public Health. 2025 Apr 30;13:1487177. doi: 10.3389/fpubh.2025.1487177. eCollection 2025. Front Public Health. 2025. PMID: 40371294 Free PMC article.
-
Evolving landscape of colorectal cancer: Global and regional burden, risk factor dynamics, and future scenarios (the Global Burden of Disease 1990-2050).Ageing Res Rev. 2025 Feb;104:102666. doi: 10.1016/j.arr.2025.102666. Epub 2025 Jan 18. Ageing Res Rev. 2025. PMID: 39828028 Review.
-
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study.JAMA Oncol. 2018 Nov 1;4(11):1553-1568. doi: 10.1001/jamaoncol.2018.2706. JAMA Oncol. 2018. PMID: 29860482 Free PMC article.
Cited by
-
A registration trend in eyelid skin cancers and associated risk factors in Iran, 2005-2016.BMC Cancer. 2023 Sep 30;23(1):924. doi: 10.1186/s12885-023-11414-z. BMC Cancer. 2023. PMID: 37777736 Free PMC article.
-
The effect of COVID-19 on surgical management of skin cancers of the head, face and neck in elderly patients.Skin Health Dis. 2023 Mar 28;3(2):e175. doi: 10.1002/ski2.175. eCollection 2023 Apr. Skin Health Dis. 2023. PMID: 37025367 Free PMC article.
-
Superficial Basal Cell Carcinoma on the Back Region Treated with a Combination of Cryotherapy and 5% Imiquimod Cream: A Case Report.Int Med Case Rep J. 2023 Jun 26;16:391-396. doi: 10.2147/IMCRJ.S409840. eCollection 2023. Int Med Case Rep J. 2023. PMID: 37398930 Free PMC article.
-
Burden of esophageal cancer in global, regional and national regions from 1990 to 2021 and its projection until 2050: results from the GBD study 2021.Front Oncol. 2025 Jan 20;14:1518567. doi: 10.3389/fonc.2024.1518567. eCollection 2024. Front Oncol. 2025. PMID: 39902130 Free PMC article.
-
Risk Factors and Innovations in Risk Assessment for Melanoma, Basal Cell Carcinoma, and Squamous Cell Carcinoma.Cancers (Basel). 2024 Feb 29;16(5):1016. doi: 10.3390/cancers16051016. Cancers (Basel). 2024. PMID: 38473375 Free PMC article. Review.
References
-
- Lomas A, Leonardi‐Bee J, Bath‐Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166(5):1069‐1080. - PubMed
-
- Gordon R. Skin cancer: an overview of epidemiology and risk factors. Semin Oncol Nurs. 2013;29(3):160‐169. - PubMed
-
- Cameron MC, Lee E, Hibler BP, et al. Basal cell carcinoma: epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. J Am Acad Dermatol. 2019;80(2):303‐317. - PubMed
-
- Fitzmaurice C, Abate D, Abbasi N, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability‐adjusted life‐years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5(12):1749–1768. - PMC - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials